rolling out our ggr strategy
play

Rolling Out Our GGR Strategy Jacob Winter, Global Generic Resources - PowerPoint PPT Presentation

Rolling Out Our GGR Strategy Jacob Winter, Global Generic Resources September 9, 2008 Jerusalem Key Themes Goal of Global Enable Teva to win Goal of Global Enable Teva to win in all markets where Generic in all markets where Generic we


  1. Rolling Out Our GGR Strategy Jacob Winter, Global Generic Resources September 9, 2008 Jerusalem

  2. Key Themes Goal of Global Enable Teva to win Goal of Global Enable Teva to win in all markets where Generic in all markets where Generic we compete we compete Resources Resources �

  3. Key Pillars of Our Strategy Increase Teva’s Increase Teva’s � Extend leadership in U.S. market share in market share in � Establish leadership in key EU and International markets key markets key markets � Double R&D capabilities Double our Double our � Focus on first-to-market / Paragraph IVs product portfolio product portfolio � Double production capacity � Develop big-to-big offerings Redefine Redefine � Create new go-to-market initiatives customer service customer service Biotechnology: Biotechnology: � Invest in the next wave of technology and Generics Next growth Next growth � Create affordable Biogenerics: lower cost , greater value wave in generics wave in generics � Focus on niche specialty areas Innovative Innovative � Leverage unique sourcing, development and go-to- business business market approaches �

  4. Key Pillars of Our Strategy ���� Achieve 2x Submissions Achieve 2x Submissions � Globalize and Integrate product selection Increase Teva’s Increase Teva’s � Develop Earlier market share in market share in key markets � Strengthen Scientific Know-how key markets � Establish Regional Managers: US, EU, International Double our Double our � Globalize Biopharmaceutics product portfolio product portfolio � Focus on Value and Quality of Submissions �

  5. Teva Global Generic R&D Sites ��3��$�!�$ 45� ��"�������� ������� ������� �� �������� ������ , ������� ������� "����!� � ��� ����-�/ &�����2� ����-./ ������$(�������� ��(������� ��0��) ����� 0��1������ ������ %���&���� ������ %������� �'�����(��)�����*���!����� +���$���� ���� ���������������� �����"��� �������#����$�����$ ����� ��� ������!���� �

  6. Global Portfolio Uses U.S. as Springboard ��(���������<���< 6778 6747 � ������(��� ���! � :������!����!��1�����= 9��������:���$ 465 �����!1��������� � #���>��(�������$!����$ � ����'��!������ ����$$ ���1����!'�����%����;�"�!���%���������%����� ���:��� �� ��� ��$!*�''��!�(�� ��!�=���!�� ���� ������ ��!����!������ ���?�!$ �

  7. What Makes Teva Generic R&D Successful � Truly globalized Generic R&D � People and management experience � Legal and regulatory expertise � Leveraging files between markets � Vertical integration with Teva API � Teva is a preferred customer (API vendors, CRO’s) �

  8. Key Pillars of Our Strategy Increase Teva’s Increase Teva’s � Extend leadership in U.S. market share in market share in � Establish leadership in key EU and International markets key markets key markets � Double R&D capabilities Double our Double our � Focus on first-to-market / Paragraph IVs product portfolio product portfolio � Double production capacity � Develop big-to-big offerings Redefine Redefine � Create new go-to-market initiatives customer service customer service Biotechnology: Biotechnology: � Invest in the next wave of technology and Generics Next growth Next growth � Create affordable Biogenerics: lower cost , greater value wave in generics wave in generics � Focus on niche specialty areas Innovative Innovative � Leverage unique sourcing, development and go-to- business business market approaches �

  9. Key Pillars of Our Strategy ���������� Supply Chain Infrastructure Supply Chain Infrastructure � Double manufacturing infrastructure � Develop “customer focused” packaging solutions Increase Teva’s Increase Teva’s � Adjust the plant-product portfolio according to the market share in market share in strategic profiling key markets key markets � Invest in Quality and GMP compliance � Improve effectiveness and competitiveness Double our Double our product portfolio product portfolio Supply Chain Processes Supply Chain Processes � Build segmented “End-to-End” Supply chain processes Redefine Redefine customer service customer service � Build “End-to-End” new product launch processes � Increase back integration with Teva API � Complete the supporting IT systems �

  10. Operations – Global Presence ����'��!������$�!�$�����@7� �)���� ������� ��!�� .�!��'��� �� ������ �&��� ��$!������ �!��''(���� ) �(� ������� ������� @7���(� �������� ��"�������� �������, ������� ������� :����� � ��� ���$ ����-�/ &�����2� ������$(�������� ����-./ ������$���� ������ ��(������� :���'�������+ �'�����(��)�����*���!����� ��0��) �������:� +���$�����-3��� 1�/� 0��1������ +��)�� "����� �$1��� ����$����2 � "��� �� %���&���� %������� ���� ���������������� �����"��� Employees A44�777 �������#����$�����$ ����� BC�577 ��� ������!���� ��

  11. Wide Range of Technologies Tablets, Capsules, MR Tablets, Powders for suspension Pre-filled syringes, Vials, Ampoules, Infusion Bags, Nebules (BFS), Ophthalmics Metered Dose Inhalers (MDI’s) Metered Dose Powder Inhalers (MDPI’s) Breath Actuated Inhalers (BAI’s) Liquids, Creams & Ointments, Nasal sprays, Suppositories, SGC’s ��

  12. Unmatched Capacity – Foundation For Global Leadership Volume Planned capacity to exceed 90B by 2012 Planned capacity to exceed 90B by 2012 Produces Tabs/Caps ��� �� ~90B �� ! ! Double �� Our �� Capacity �� * * �� �� 22B 22B June YTD June YTD �� 15B �� 3B * Current pace ~44B/year 2012 1995 2000 2005 2008 ��

  13. Quality System Approach D����!=�#=���$��� D����!=�#=����'������� #�������*���>����!=�'���� ��� �������<�!1�������!��=� ��(��� ���!�!1����1��!��� ��>�������!$���������������� �����!F$���'�*�=��� ���� �����!�$ ���'���!���$ D����!=����'��� ��!�����������E!������ �$$�$$���! �'�!1��>����!=� ��'������� ��

  14. Teva and Barr Strong strategic fit with attractive economics � Generic R&D capabilities � Production infrastructure � Women’s health segment � Potential synergies: � GR&D � Pharmaceutical production � Teva API � Materials purchasing ��

  15. Global Leadership � Double portfolio value and capacity of global core functions Enable Teva to win in all � Enable Teva to win in all Maintain and enhance markets where we markets where we service leadership compete compete � Separate from the pack – unmatched global generic resources ��

  16. Thank You! ��

Recommend


More recommend